![Mark Lewis: I cannot abide this cowardly callousness by another doctor who must know that delays can cause real harm](https://oncodaily.com/pub/uploads/2023/08/Mark-Lewis-2-e1693522297639-1280x1175.jpg)
Mark Lewis: I cannot abide this cowardly callousness by another doctor who must know that delays can cause real harm
Quoting Mark Lewis on X/Twitter:
“NEW INSURANCE TACTIC JUST DROPPED!
A ‘peer’ reviewer approved a drug over the phone then reversed their decision in writing WITHOUT TELLING ME OR THE PATIENT INVOLVED. I cannot abide this cowardly callousness by another doctor who must know that delays can cause real harm! (adding insult to injury, the bait-and-switch phone call was — of course — scheduled at an inconvenient time of the arbiter’s own choosing in the middle of our busy clinic, and, in the Year of Our Lord 2023, the craven denial arrived much later by fax:).”
Source: Mark Lewis/Twitter.
Mark A. Lewis is the Director of Gastrointestinal Oncology at Intermountain Healthcare in Utah, the Co-Chair of adolescent & young adult (AYA) oncology in the SWOG cooperative group, and the Vice President of American Multiple Endocrine Neoplasia Support. Dr. Lewis is also a well-known patient advocate and social media influencer.
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023